Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 7 Sept 2026Clinical review pending
!
Suspected orbital cellulitis needs admission
Infection behind the orbital septum can damage the optic nerve, form an abscess or spread intracranially.
Action: Arrange immediate hospital assessment with ophthalmology and ENT, begin appropriate intravenous antibiotics promptly and obtain indicated contrast imaging without delaying treatment.
Synopsis
Distinguish superficial eyelid infection from postseptal disease, recognise a limited examination as a risk factor and arrange timely antibiotics, imaging and surgical review.
Preseptal infection lies anterior to the orbital septum and should preserve ocular function.
Orbital cellulitis affects deeper tissues and is a sight-threatening and potentially life-threatening infection.
Normal acuity alone does not exclude early orbital disease.
Key red flags
Painful or restricted eye movements, binocular diplopia or proptosis.
Investigation priorities
01
Documented serial eye examinationFirst step
Establish baseline function and detect deterioration during treatment.
Management branches
Orbital disease possibleAdmit and coordinate urgent treatment
An orbital sign, serious illness or unreliable examination raises concern.
Arrange urgent hospital assessment with ophthalmology, ENT and age-appropriate medical support.
Start empirical intravenous treatment under the relevant orbital-infection protocol without waiting for scan results.
Selected mild preseptal diseaseUse oral treatment with active review
The patient is stable and the eye examination is reliably normal.
Key medicines
Co-amoxiclav for selected adult preseptal cellulitisNICE specifies 500 mg/125 mg orally three times daily for seven days for infection near the eyes or nose.
Ceftriaxone with metronidazole for adult orbital cellulitisThe cited Oxford protocol uses ceftriaxone 2 g intravenously once daily plus metronidazole 400 mg orally three times daily, with daily review and seven-to-fourteen-day total treatment.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.